How to Fix Central Sleep Apnea: Your Treatment Options

Central sleep apnea (CSA) is treatable, but the right approach depends heavily on what is causing it. Unlike the more common obstructive type, where a physical blockage collapses the airway, CSA happens because the brain temporarily stops sending the signal to breathe during sleep. That distinction matters because it changes everything about treatment. A therapy that works well for heart-failure-related CSA can be dangerous for some patients, while a medication that helps one subtype does little for another. The good news is that the treatment landscape has expanded considerably, with options ranging from airway pressure devices and implanted nerve stimulators to oxygen therapy, medications, and targeted management of the underlying condition driving the problem.

Why Central Sleep Apnea Happens

Understanding the cause shapes every treatment decision. At its core, CSA results from an unstable breathing control system. The brain’s respiratory center and the lungs work in a feedback loop to keep carbon dioxide (CO2) levels steady. When that loop overreacts, breathing can swing between too much and too little, dipping below the threshold that triggers the next breath. Researchers describe this instability as “high loop gain,” meaning the system’s response to small changes in CO2 is too aggressive, producing an overshoot-and-undershoot cycle instead of steady breathing.¹

The most common trigger is heart failure. Roughly 40% of people with congestive heart failure have CSA, often with a characteristic waxing-and-waning breathing pattern called Cheyne-Stokes respiration.² In these patients, fluid congestion in the lungs and a sluggish circulation time between the lungs and the brain delay the feedback signals, making the loop even more unstable.³ Chronic opioid use is another well-established cause. There is a clear dose-response relationship: the higher the opioid dose, the more central apneas and irregular breathing patterns appear during sleep.⁴ High altitude can also trigger CSA in otherwise healthy people, because the low-oxygen environment drives hyperventilation that pushes CO2 below the threshold for stable breathing during lighter stages of sleep.⁵

CPAP as the Standard First-Line Treatment

Continuous positive airway pressure (CPAP) is considered the initial treatment for most forms of CSA, particularly when heart failure is involved. Practice guidelines describe CPAP as the standard first step, based on the weight of available evidence across CSA subtypes.⁶ CPAP works in CSA partly by keeping the airway splinted open but also by raising the baseline CO2 level slightly, which can help stabilize the feedback loop and prevent the CO2 from dropping below the apnea threshold.

CPAP does not work for everyone with CSA, though. Some patients’ central apneas persist or even worsen despite optimal CPAP pressure. And there is a separate, somewhat confounding phenomenon: treatment-emergent central sleep apnea (TECSA), where someone being treated for obstructive sleep apnea with CPAP develops new central apneas they did not have before. One study found that about 17% of obstructive apnea patients developed central apneas during CPAP titration.⁷ The reassuring side of TECSA is that it resolves on its own in many patients with continued CPAP use. For those whose central apneas persist, other approaches become necessary.⁸

Adaptive Servo-Ventilation and Its Critical Limitation

Adaptive servo-ventilation (ASV) is a more sophisticated form of positive airway pressure that adjusts its support breath by breath, backing off when you are breathing well and ramping up when your breathing weakens or pauses. For many forms of CSA, ASV does an excellent job of normalizing breathing metrics. In clinical trials, it has reduced the average apnea-hypopnea index to well within the normal range.

But a landmark trial fundamentally changed how ASV is used. The SERVE-HF trial enrolled patients with heart failure who had a reduced ejection fraction (the heart’s pumping strength was significantly weakened) and CSA. The results were alarming: patients using ASV had a roughly 28% higher risk of dying from any cause and a 34% higher risk of cardiovascular death compared to those receiving standard care alone.⁹ ASV is now contraindicated in patients with heart failure whose ejection fraction is significantly reduced. The prevailing theory is that positive airway pressure in these patients interferes with the heart’s ability to fill and pump effectively, worsening cardiac function even while normalizing breathing.

This finding does not mean ASV is dangerous for everyone with CSA. For patients whose CSA is not related to reduced-ejection-fraction heart failure, such as those with opioid-related CSA, idiopathic CSA, or treatment-emergent CSA that will not resolve, ASV remains a viable and often effective option. The key is careful patient selection, which is why sleep specialists and cardiologists typically need to coordinate before ASV is prescribed.

Bilevel Positive Airway Pressure

Bilevel positive airway pressure (often called BiPAP) provides different pressures for inhalation and exhalation, and when set to a spontaneous-timed mode, it delivers a backup breath if you go too long without breathing on your own. Practice guidelines position bilevel therapy as a later-line option for heart-failure-related CSA, recommended only after CPAP, ASV, and oxygen have been tried without adequate response.⁶ In pediatric patients with CSA, bilevel PAP with a backup breathing rate is actually the most commonly used treatment, reflecting the different mix of underlying causes in children.¹⁰

Phrenic Nerve Stimulation

This is the newest category of CSA treatment and works on a completely different principle from airway pressure devices. A small device is implanted in the chest, similar to a pacemaker, with a lead positioned near the phrenic nerve, which controls the diaphragm. During sleep, the device detects pauses in breathing and sends a mild electrical signal to the nerve, causing the diaphragm to contract and generate a breath. The mechanism produces negative intrathoracic pressure, the same kind your body generates during normal breathing, which actually helps blood flow back to the heart rather than fighting against it as positive pressure devices do.¹¹ That distinction is especially relevant for heart failure patients, given the problems ASV caused in the SERVE-HF trial.

Five-year follow-up data on the remedē System (the only FDA-cleared phrenic nerve stimulator for CSA) show sustained improvements. The central apnea index dropped from a median of 23 events per hour at baseline to just 1 event per hour at five years. The overall apnea-hypopnea index fell from 46 to 17 events per hour, and patients’ daytime sleepiness also improved.¹² At least 60% of patients achieved a 50% or greater reduction in their apnea-hypopnea index through 24 months.¹³ Serious complications related to the implant, device, or therapy were reported by about 14% of patients over five years, mostly involving repositioning of the device or lead revision in the first year, and none caused lasting harm.¹²

Phrenic nerve stimulation is not a first-line treatment and is generally reserved for patients with moderate-to-severe CSA who have not responded to or cannot tolerate other therapies. The surgical implant and cost put it firmly in the specialist referral category. But for patients who have run out of standard options, particularly those with heart failure where ASV is off the table, it fills a real gap.

Supplemental Oxygen

Breathing low-flow oxygen during sleep is one of the older and simpler approaches to CSA. It works by blunting the hypoxic drive that contributes to the ventilatory instability behind central apneas. In one study of 20 patients, nighttime oxygen reduced central apneas and hypopneas from a median of about 34 per hour to 5 per hour, and more than 85% of patients had at least a 50% reduction in events. The benefit held regardless of whether the patient had heart failure.¹⁴

The open question with supplemental oxygen is whether improving the breathing numbers translates to improved survival and cardiovascular outcomes. Oxygen clearly reduces central apnea events, but whether this changes the course of the underlying disease, especially in heart failure patients, remains under active investigation.¹⁵ For now, oxygen is generally positioned as a reasonable option, particularly when CPAP alone has not controlled the apneas, and in patients for whom ASV is contraindicated.

Medications That Can Help

No drug is specifically approved for CSA, but several have shown real effects in clinical studies, and sleep specialists sometimes use them off-label.

Acetazolamide is the best-studied medication for CSA. It is a mild diuretic that causes a slight metabolic acidosis, which stimulates the brain’s drive to breathe and raises the CO2 threshold for apnea. A meta-analysis of available studies found that acetazolamide significantly reduced the apnea-hypopnea index in central sleep apnea patients, improved blood oxygen levels, and modestly improved total sleep time and sleep efficiency.¹⁶ It has also been used in pediatric cases where other treatments are impractical.¹⁷ The main downsides are side effects including tingling in the fingers and toes, taste changes, and the risk of electrolyte imbalances with long-term use.

Theophylline, a medication better known for treating asthma, has also shown promise. In a randomized crossover trial of heart failure patients with CSA, theophylline cut central apneas per hour from about 26 to 6 and substantially reduced time spent with low oxygen levels during sleep.¹⁸ However, theophylline has a narrow safety margin. Too-high levels in the blood can cause heart rhythm problems, and in patients who already have heart failure this risk warrants caution. A Cochrane systematic review of pharmacological treatments for CSA classified the evidence for both acetazolamide and theophylline as very low certainty, not because the drugs showed no effect but because the studies were small and short-term.¹⁹ In practice, these medications are typically considered adjuncts or options for patients who cannot use device-based therapies, not standalone treatments.

CO2 Manipulation

Since CSA fundamentally arises from CO2 dropping below the threshold that triggers breathing, researchers have explored directly preventing that drop. One approach is enhanced expiratory rebreathing space, essentially adding dead space to a positive pressure mask so the patient rebreathes a small amount of their own exhaled CO2. This raises CO2 just enough to keep it above the apnea threshold.²⁰

A more precise version involves delivering a small, individually titrated amount of CO2 through a specialized mask. In a recent study, this approach reduced the apnea-hypopnea index from about 31 to 6 events per hour, improved sleep efficiency, and shortened the time it took patients to fall asleep, all without raising heart rate.²¹ Researchers have even tested dynamic CO2 delivery that times small CO2 puffs to coincide with the hyperventilation phase of the breathing cycle. In heart failure patients, this approach reduced breathing oscillations by about two-thirds while keeping average CO2 and ventilation levels unchanged.²²

CO2 manipulation is still largely experimental, and none of these approaches are widely available as a standard clinical treatment. But they represent a fundamentally different angle of attack, targeting the root instability in the breathing control loop rather than mechanically overriding it.

Treating the Underlying Cause

Sometimes the most effective treatment for CSA is not a device or drug aimed at breathing during sleep but rather better management of whatever is driving the instability. In heart failure, optimizing medications, managing fluid overload, and improving cardiac function can reduce or eliminate CSA. Evidence shows that effective heart failure treatment increases the heart’s pumping strength and improves survival in patients who also have CSA.²

For opioid-related CSA, reducing the opioid dose is the most direct intervention. The relationship between opioids and central apneas is dose-dependent, and lowering the dose can diminish the central apneas.²³ At morphine-equivalent doses of 200 mg or higher, the odds of developing irregular breathing patterns during sleep increase dramatically.⁴ When opioids cannot be reduced because of pain management needs, ASV or bilevel PAP with a backup rate may be used to manage the breathing disturbance directly.

Altitude-related CSA generally resolves when a person returns to lower elevation. At altitude, the body’s response to low oxygen drives hyperventilation, which pushes CO2 low enough to destabilize breathing during sleep.²⁴ Acclimatization helps somewhat but does not fully resolve the problem because both the oxygen and CO2 responsiveness of the respiratory system increase over time, which partially offsets the adaptation.⁵ Acetazolamide is commonly used for high-altitude CSA because it directly addresses the CO2 imbalance driving the instability.

Positional Therapy

This one surprises people, because positional therapy is primarily associated with obstructive sleep apnea. But a subset of CSA patients have apneas that are significantly worse when sleeping on their back. In a study using a wearable positional device that vibrates to discourage supine sleeping, patients with positional CSA saw their apnea-hypopnea index drop from a median of about 23 events per hour to roughly 12 after one month and below 10 after six months. Supine sleep time dropped from about 38% of the night to under 7%.²⁵

Positional therapy is not going to solve severe CSA on its own, and the effect of body position on central apneas is less well understood than its effect on obstructive ones.²⁶ But for patients who have a clear positional component to their CSA, it can be a useful supplement to other treatments, and its simplicity and lack of side effects are appealing.

Central Sleep Apnea in Children

Pediatric CSA deserves its own mention because it looks quite different from the adult version. In a review of over 1,200 children evaluated at a sleep lab, about 10% had CSA. The most common underlying conditions were genetic syndromes like Down syndrome and Prader-Willi syndrome, followed by neurological disorders. More than 80% of these children also had obstructive apneas alongside their central ones. And notably, fewer than 60% of parents had reported symptoms suggesting a breathing problem during sleep, meaning CSA in children often flies under the radar.¹⁰

Treatment in children leans heavily on bilevel PAP with a backup breathing rate. The medication options are more limited, though acetazolamide has been used successfully in individual cases where device therapy was not feasible.¹⁷ The underlying condition driving CSA in children often requires its own management, making a multidisciplinary approach especially important.

Choosing the Right Treatment Path

The sheer number of options can feel overwhelming, but in practice the decision tree narrows quickly based on the cause and severity of CSA. For most adults, the starting point is CPAP combined with aggressive management of any underlying condition like heart failure or opioid use. If CPAP alone does not control the central apneas, the next step depends on the clinical picture. Patients without reduced-ejection-fraction heart failure can trial ASV. Supplemental oxygen or acetazolamide can be layered in. For patients with heart failure and reduced pumping function, where ASV is off the table, oxygen therapy, phrenic nerve stimulation, or bilevel PAP with a backup rate become the main device options.

One practical reality worth knowing: CSA can shift over time. Heart failure that improves with medication may see its associated CSA diminish or disappear. Treatment-emergent central apneas that appear with CPAP often resolve within weeks to months of continued use. An opioid taper can progressively reduce central events. So the treatment plan for CSA is not necessarily static. Regular follow-up sleep studies help track whether what you are doing is still what you need to be doing, and sleep specialists typically expect to revisit the approach as the underlying picture evolves.

1
American Journal of Respiratory and Critical Care Medicine. Pathogenesis of Obstructive and Central Sleep Apnea
2
PubMed Central. Central sleep apnoea syndrome in chronic heart failure: an underestimated and treatable comorbidity
3
PubMed. Central Sleep Apnea with Cheyne-Stokes Breathing in Heart Failure – From Research to Clinical Practice and Beyond
4
PubMed Central. Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing
5
PubMed. Central Sleep Apnea at High Altitude
6
Sleep. The Treatment of Central Sleep Apnea Syndromes in Adults: Practice Parameters with an Evidence-Based Literature Review and Meta-Analyses
7
PubMed. The prevalence and polysomnographic characteristics of treatment-emergent central sleep apnea with obstructive sleep apnea
8
PubMed Central. Treatment-emergent central sleep apnea: a unique sleep-disordered breathing
9
PubMed Central. Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure
10
PubMed Central. Central Sleep Apnea in Children—10 Years Experience at a Tertiary Sleep Laboratory
11
European Journal of Heart Failure. Phrenic Nerve Stimulation to Treat Patients with Central Sleep Apnoea and Heart Failure
12
PubMed Central. Transvenous Phrenic Nerve Stimulation for Treatment of Central Sleep Apnea: Five-Year Safety and Efficacy Outcomes
13
PubMed Central. Long-term efficacy and safety of phrenic nerve stimulation for the treatment of central sleep apnea
14
PubMed. Reversal of central sleep apnea with oxygen
15
PubMed. Oxygen Therapy in Sleep-Disordered Breathing
16
PubMed Central. The role of acetazolamide in sleep apnea at sea level: a systematic review and meta-analysis
17
PubMed. Acetazolamide as a therapeutic alternative for central sleep apnea in pediatric patient with FBXO28 gene mutation: A case report and review of literature
18
PubMed. Effect of theophylline on sleep-disordered breathing in heart failure
19
PubMed Central. Pharmacological treatment for central sleep apnoea in adults
20
PubMed Central. Alternative approaches to treatment of Central Sleep Apnea
21
PubMed. Central sleep apnea treated by a constant low-dose CO(2) supplied by a novel device
22
PubMed. Real-time dynamic carbon dioxide administration: a novel treatment strategy for stabilization of periodic breathing with potential application to central sleep apnea
23
American Journal of Respiratory and Critical Care Medicine. Opioid-Related Central Sleep Apnea Not Detrimental to Key Respiratory and Sleep Parameters: Results from the Opsafe Multicentre Trial
24
PubMed. Central Sleep Apnea at High Altitude: From Pathophysiology to Treatment
25
PubMed. New-generation positional therapy in patients with positional central sleep apnea
26
PubMed Central. A case of positional central sleep apnea